Skip to main content

Table 2 Univariate and multivariate Cox regression analysis for overall survival in the rIII-IVA* NPC

From: Correction: Prognostic value of pre-treatment [18F] FDG PET/CT in recurrent nasopharyngeal carcinoma without distant metastasis

Characteristics

Univariable analysis

P

Multivariate analysis

P

HR (95% CI)

HR (95% CI)

Age (years)

    

 < 45

1 (reference)

   

 ≥ 45

1.090 (0.685-1.733)

0.717

  

Sex

    

 Male

1 (reference)

   

 Female

1.372 (0.775-2.428)

0.278

  

rEBV DNA (copies/ml)

    

 Undetectable

1 (reference)

   

 Detectable

1.612 (0.899-2.889)

0.109

  

 Unkown

    

rLactate dehydrogenase (U/L)

    

 < 240

1 (reference)

   

 ≥ 240

1.104 (0.347-3.518)

0.867

  

 Unkown

/

   

rC-reactive protein (mg/L)

    

 < 10.5

1 (reference)

 

1 (reference)

 

 ≥ 10.5

2.784 (1.615-4.798)

<0.001

2.348 (1.336-4.127)

0.003

rAlbumin (g/L)

    

 < 39.4

1 (reference)

 

1 (reference)

 

 ≥ 39.4

0.195 (0.107-0.356)

<0.001

0.224 (0.120-0.418)

<0.001

rNLR

    

 < 3.7

1 (reference)

   

 ≥ 3.7

1.372 (0.855-2.203)

0.190

  

 Unkown

/

   

Treatment

    

 Palliative treatment

1 (reference)

 

1 (reference)

 

 Re-radiotherapy+Salvage Surgery

0.340 (0.210-0.551)

<0.001

0.407 (0.249-0.666)

<0.001

PET/CT

    

 No

1 (reference)

 

1 (reference)

 

 Yes

0.519 (0.294-0.917)

0.024

0.476 (0.267-0.847)

0.012

  1. Abbreviations r: Recurrent; EBV: epstein-barr virus; NLR: neutrophil-to-lymphocyte ratio; HR: hazard ratio; 95% CI: 95% confidence interval; NPC: nasopharyngeal carcinoma; MRI: magnetic resonance imaging; PET/CT: positron emission tomography/computed tomography
  2. *Based on the eighth edition of the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) staging system according to MRI
  3. Using the Cox regression model to calculate HR and 95% CI